company background image
301130 logo

Jilin Province Xidian Pharmaceutical Sci-Tech DevelopmentLtd SZSE:301130 Stock Report

Last Price

CN¥23.90

Market Cap

CN¥1.9b

7D

1.6%

1Y

-14.5%

Updated

12 Jul, 2024

Data

Company Financials

Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.,Ltd

SZSE:301130 Stock Report

Market Cap: CN¥1.9b

301130 Stock Overview

Engages in the research and development, production, and sale of chemical raw materials and pharmaceutical preparations in China.

301130 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance3/6
Financial Health6/6
Dividends2/6

Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.,Ltd Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Jilin Province Xidian Pharmaceutical Sci-Tech DevelopmentLtd
Historical stock prices
Current Share PriceCN¥23.90
52 Week HighCN¥36.00
52 Week LowCN¥15.20
Beta0.58
11 Month Change0%
3 Month Change2.14%
1 Year Change-14.49%
33 Year Changen/a
5 Year Changen/a
Change since IPO-58.08%

Recent News & Updates

Jilin Province Xidian Pharmaceutical Sci-Tech DevelopmentLtd (SZSE:301130) Is Increasing Its Dividend To CN¥0.26

Jun 07
Jilin Province Xidian Pharmaceutical Sci-Tech DevelopmentLtd (SZSE:301130) Is Increasing Its Dividend To CN¥0.26

Jilin Province Xidian Pharmaceutical Sci-Tech DevelopmentLtd (SZSE:301130) Strong Profits May Be Masking Some Underlying Issues

Apr 29
Jilin Province Xidian Pharmaceutical Sci-Tech DevelopmentLtd (SZSE:301130) Strong Profits May Be Masking Some Underlying Issues

Recent updates

Jilin Province Xidian Pharmaceutical Sci-Tech DevelopmentLtd (SZSE:301130) Is Increasing Its Dividend To CN¥0.26

Jun 07
Jilin Province Xidian Pharmaceutical Sci-Tech DevelopmentLtd (SZSE:301130) Is Increasing Its Dividend To CN¥0.26

Jilin Province Xidian Pharmaceutical Sci-Tech DevelopmentLtd (SZSE:301130) Strong Profits May Be Masking Some Underlying Issues

Apr 29
Jilin Province Xidian Pharmaceutical Sci-Tech DevelopmentLtd (SZSE:301130) Strong Profits May Be Masking Some Underlying Issues

Shareholder Returns

301130CN PharmaceuticalsCN Market
7D1.6%2.1%1.6%
1Y-14.5%-16.4%-18.4%

Return vs Industry: 301130 exceeded the CN Pharmaceuticals industry which returned -16.4% over the past year.

Return vs Market: 301130 exceeded the CN Market which returned -18.4% over the past year.

Price Volatility

Is 301130's price volatile compared to industry and market?
301130 volatility
301130 Average Weekly Movement5.4%
Pharmaceuticals Industry Average Movement5.8%
Market Average Movement6.7%
10% most volatile stocks in CN Market10.0%
10% least volatile stocks in CN Market4.3%

Stable Share Price: 301130 has not had significant price volatility in the past 3 months.

Volatility Over Time: 301130's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1990269Jun Zhangxidianyy.com

Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.,Ltd engages in the research and development, production, and sale of chemical raw materials and pharmaceutical preparations in China. The company provides drugs for the treatment of anemia, mental disorders, cardiovascular and cerebrovascular diseases, and tumors. It provides drugs in the form of tablets and capsules.

Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.,Ltd Fundamentals Summary

How do Jilin Province Xidian Pharmaceutical Sci-Tech DevelopmentLtd's earnings and revenue compare to its market cap?
301130 fundamental statistics
Market capCN¥1.86b
Earnings (TTM)CN¥54.97m
Revenue (TTM)CN¥236.76m

34.0x

P/E Ratio

7.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
301130 income statement (TTM)
RevenueCN¥236.76m
Cost of RevenueCN¥49.62m
Gross ProfitCN¥187.13m
Other ExpensesCN¥132.16m
EarningsCN¥54.97m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Aug 29, 2024

Earnings per share (EPS)0.70
Gross Margin79.04%
Net Profit Margin23.22%
Debt/Equity Ratio0%

How did 301130 perform over the long term?

See historical performance and comparison

Dividends

1.1%

Current Dividend Yield

38%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.